Work

A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.3152

Authors: Mohamed Alaa Gouda, Jenny Shunyakova, Aung Naing, Ecaterina Elena Dumbrava, David S. Hong, Ying Yuan, Peiying Yang, Alan Myers, Yulong Liang, Jing Ping, Daniel D. Karp, Apostolia Maria Tsimberidou, Jordi Rodon Ahnert, Timothy A. Yap, Sarina A. Piha-Paul, Funda Meric-Bernstam, Siqing Fu

Institutions: The University of Texas MD Anderson Cancer Center, University of Missouri–Kansas City, The University of Texas Health Science Center at Houston

Language: English

Topic: Cancer Treatment and Pharmacology

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4400274237

Cites:

Cited by: 1

Related to: 10